Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -0.05% is 100% above its 4-year average of -64.28%, near the high end of its 4-year range (-154.49%–-0.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 99.89% above its 12-month average of -46.38%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -0.05%.
RETURN ON EQUITY (ROE)
-0.05%
RETURN ON EQUITY (ROE) AVG TTM
-46.38%
RETURN ON EQUITY (ROE) AVG 3Y
-44.58%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+99.89%
CURRENT VS 3Y AVG
+99.89%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.42%
median of 462 covered companies
CURRENT VS SECTOR MEDIAN
+99.87%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$114.47M
Return on Equity (ROE)
-0.05%
TTM Avg
-46.38%
3Y Avg
-44.58%
5Y Avg
N/A
Market Cap
$114.76M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$111.89M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$115.66M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
Market Cap
$116.84M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$112.31M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
Market Cap
$111.78M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$117.03M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$110.75M
Return on Equity (ROE)
-80.97%
TTM Avg
-121.11%
3Y Avg
-93.50%
5Y Avg
-70.15%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $114.47M | -0.05% | -46.38% | -44.58% | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | -57.47% | -26.63% | 16.73% | 210.40% |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | -478.26% | -687.50% | 165.05% | 111.70% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | -93.44% | -8.16% | 13.24% | 13.24% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | N/A | 129.36% | -24207.46% | -16163.58% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.31M | -44.29% | -31.86% | -53.29% | -49.85% |
| BGM Group Ltd. (BGM)vs › | $111.78M | -5.10% | -4.24% | -6.16% | 0.09% |
| Genelux Corporation (GNLX)vs › | $117.03M | -209.73% | -196.07% | -130.72% | -67.26% |
| Apyx Medical Corporation (APYX)vs › | $110.75M | -80.97% | -121.11% | -93.50% | -70.15% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | -105.40% | -90.09% | -60.23% | -18.64% |
ROE
-0.1%
ROA
-0.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -0.05% |
| 2026-03-31 | -43.14% |
| 2025-12-31 | -49.33% |
| 2025-09-30 | -67.56% |
| 2025-06-30 | -71.84% |
| 2025-03-31 | -51.35% |
| 2024-12-31 | -37.60% |
| 2024-09-30 | -33.42% |
| 2024-06-30 | -28.65% |
| 2024-03-31 | -31.81% |
| 2023-12-31 | -22.42% |
| 2023-09-30 | -122.53% |
| 2023-06-30 | -97.83% |
| 2023-03-31 | -82.20% |
| 2022-03-31 | -154.49% |
| 2021-12-31 | -134.25% |
